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possible, when what they mean is that
the probability (P value) is less than
.0001. They do not state in the table
to what test or null hypothesis the P
value refers, so it is not possible for
the reader to interpret the statistical
significance.
Second, Marra and colleagues1 re-
port that remediastinoscopy is associ-
ated with 100% specificity. That in
itself is to be expected, simply
because for the vast majority of tests
(endobronchial ultrasonography in-
cluded) performed with diagnostic bi-
opsy, when tumor is seen in a biopsy
specimen, it is invariably confirmed
on the reference test (there would be
serious problems if tumor diagnosed
on the index test proved to be normal
on the reference test). Therefore spec-
ificity (ability to rule in disease) is not
the major focus for surgeons when
evaluating remediastinoscopy for re-
staging the mediastinum. The same
specificity will be obtained with any
other tests combined with tissue bi-
opsy, such as endobronchial ultraso-
nography (as referenced by Marra
and colleagues1).
Third, what is critical is sensitivity
(the ability to rule out disease), so that
patients with residual N2 disease
are not brought to operation mistak-
enly, and the reported sensitivity for
remediastinoscopy was 61%. It is im-
portant for readers to bear in mind
that sensitivity truly starts at 50% (a
test with no sensitivity, or equipoise),
not 0%. Marra and colleagues1 do not
report a confidence interval for this es-
timate; when one is calculated, it ranges
from 42% to 77%. That is, it crosses
50%. This low value of sensitivity is
entirely in keeping with the previous
literature on remediastinoscopy. De
Leyn and associates2 attributed this to
the technical difficulty in obtaining ad-
equate biopsy specimens from the areas
of previous lymph node involvement.
Fourth, Marra and colleagues1 have
used their own arbitrary definition of
‘‘diagnostic accuracy,’’ which includes
(see footnote in their Table 3) in the de-
nominator ‘‘no biopsy.’’ This does not
comply with current Standards for
Reporting of Diagnostic Accuracy
(STARD).3 The importance of STARD
was previously highlighted by Eugene
Blackstone4 in this Journal in 2004.
We believe that compliance with
STARD is crucial for readers (which is
why it is part of this Journal’s policy),
andwe are surprised that a non–STARD
compliant article was highlighted for
continuing medical education credit.
On the basis of these findings, we
believe that the conclusion that ‘‘re-
mediastinoscopy provides a histologic
proof of mediastinal downstaging with
high diagnostic accuracy’’ cannot be
sustained by the results presented by
Marra and colleagues.1 The results do
indicate that residual disease can ruled
in with repeated mediastinoscopy, but
the procedure is unable to rule out
residual mediastinal disease with any
degree of certainty (sensitivity of
61%, 95% confidence interval 42%–
77%). Futile thoracotomy thus would
not be avoided for a large proportion
of patients were this technique used
to restage the mediastinum after induc-
tion chemotherapy.
Eric Lim, MB, ChB, MD, MSc,
(Biostatistics), FRCS (C-Th)
Michael Dusmet, MD, FMH
The Royal Brompton Hospital
London, UK
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We thank Drs Lim and Dusmet
for their comments. We would like to
answer some issues they addressed in
the statistical analysis of our article.
As concerns the need to report
specificity, competing methods for
mediastinal restaging are of noninva-
sive (positron emission tomography,
integrated positron emission tomogra-
phy and computed tomography), or
invasive (endoesophageal ultrasonog-
raphy with fine-needle aspiration bi-
opsy, endobronchial ultrasonography
with transbronchial needle aspiration,
remediastinoscopy) nature. Noninva-
sive methods do not provide histologic
proof of their positive findings, so spec-
ificity varies to a high of 90% (and thus
is lower than 100%). Invasive methods
are able to provide a histologic or cyto-
logic biopsy specimen of lymph nodes.
In the first case, specificity is as high
as 100%; in the second, however,
cytologic examination may yield false-
positive findings. In a review of the
literature on cytologic study in pulmo-
nary medicine, Policarpio-Nicolas and
Wick1 reported overall sensitivity and
specificity values ranging from 60%
to 96%, even in the most conscientious
laboratories and considering the in-
creased confidence of pathologists in
cytomorphologic diagnosis.
The reported value of sensitivity of
61% in our series is consistent with
the previous literature on remediasti-
noscopy (70%–83%), if slightly
lower, with the exception of the study
of De Leyn and colleagues,2 who re-
ported a disappointing 29% sensitivity
in a small series of patients. That report
was heavily biased by the inadequate
reexploration of the subcarinal station
in two thirds of cases (in which persis-
tent nodal disease was found in 50%
of cases at thoracotomy) and thus can-
not be cited as a standard reference for
the diagnostic value of remediastino-
scopy. In most cases, sensitivity values
of remediastinoscopy are comparable
to or higher than those of the other
methods for mediastinal restaging.ry c Volume 137, Number 1 255
REFERENT VALUES AND
EQUIPOISE: EDITORS’ NOTES
To the Editor:
Lim and Dusmet,1 in a letter to the
editors critiquing an article by Marra
and colleagues,2 make 4 statements
about referent values (accuracy, sensi-
tivity, specificity, positive predictive
value, and negative predictive value)3
that require clarification.
Statement 1: ‘‘Specificity (ability to
rule in disease) is not the major focus
for surgeons.’’
Referent value specificity is the
measure of the ability of a test to rule
out disease. It is defined as the number
of patients without the disease who are
identified by the test (true-negative re-
sults) divided by total number of pa-
tients without disease (true-negative
plus false-positive results).
Statement 2: ‘‘What is critical is
sensitivity (the ability to rule out dis-
ease).’’
Referent value sensitivity is a mea-
sure of the ability of a test to rule in
disease. It is defined as the number of
patients with disease who are identi-
fied by the test (true-positive results)
divided by the total number of patients
with the disease (true-positive and
false-negative results).
Statement 3: ‘‘Remediastinoscopy
is associated with 100% specificity.
That in itself is expected . when tu-
mor is seen in a biopsy it is invariably
seen on the reference test.’’
We believe these statements indi-
cate the authors are confusing spe-
cificity with sensitivity. In general,
screening tests have low sensitivity but
high specificity. As work-up continues
and the population is increasingly ‘‘en-
riched’’ with disease, sensitivity in-
creases and specificity decreases.
However, for the surgeon dealing
with this ‘‘enriched’’ population and
Letters to the EditorThe greatest problem for the correct
evaluation of sensitivity of remedias-
tinoscopy lies in the small sizes of
the series reported in the literature.
Small sample size determines wide
confidence intervals, which reflect
a lack of precision in the inference
of the diagnostic value to the general
population.
Furthermore, discussion about confi-
dence intervals is needed to correct
some confusing statements of Drs Lim
and Dusmet. Because the confidence
level represents the likelihood that
another samplewill provide the same re-
sults (in our case, diagnostic sensitivity),
a confidence level of 95%means that 95
out of 100 times, the sample percentages
will fall within the confidence intervals.
When applied to our study, this means
that sensitivity of remediastinoscopy in
95 out of 100 measurements will have
a value between 42% and 77%. In our
measurement—that is, remediastino-
scopy done by our surgical team and
pathologic examinations done by our
pathologists—sensitivity was exactly
61%. To say that this value ‘‘crosses
50%’’ makes no sense at all. The confi-
dence interval is a way of putting
a probability on what future samples
(or repeats of the earlier sampling proce-
dure with different users) would yield.
In other words, it is a way of saying
how repeatable the results are. It does
not state the definitive value of the result
(sensitivity) in the general population
(patients with non–small cell lung can-
cer after induction therapy).
Throughout the phases of design,
data collection, analysis, and report of
the study we kept in mind all STARD
items and checked the appropriateness
of our statements against the STARD
guidelines. Including ‘‘not biopsied
nodal stations’’ in the formula to calcu-
late the diagnostic accuracy is obvious,
compliant with the STARD guidelines,
and consistent with the methods of pre-
vious literature.3 For example, Drs Lim
and Dusmet cited the article of De Leyn
and colleagues,2 in which sensitivity
was calculated by including a consider-
able number of cases with inadequate256 The Journal of Thoracic andexploration of the subcarinal station
(‘‘no biopsy’’) in which residual metas-
tases were discovered at further thora-
cotomy (‘‘false-negative’’ result of
remediastinoscopy). In the evaluation
of diagnostic yield of remediastino-
scopy, inadequatebiopsyof ametastatic
lymph node station with a false-nega-
tive finding and no biopsy of the station
are two faces of the same coin, the in-
ability of the method to rule in disease,
regardless of what factor leads to the
false-negative result (fibrotic alteration
of nodal tissue after previous mediasti-
noscopy, dense adhesions with ana-
tomic inaccessibility, and so on).
Finally, we remind the readers that
the accuracy value of remediastinoscopy
was as high as 88%. The ability to rule
in residual disease (specificity) was
present in 100% of cases. The ability
to rule out residual disease (sensitivity)
was present in 61%; that is, unnecessary
thoracotomy could be avoided for about
two thirds of patients.
On the basis of these considerations,
we reaffirm our conclusion that reme-
diastinoscopy provides histologic
proof of mediastinal staging with
high diagnostic accuracy.
Alessandro Marra, MD, PhDa
Ludger Hillejan, MDb
Georgios Stamatis, MDa
Department of Thoracic Surgery and
Endoscopy
Ruhrlandklinik
Essen, Germanya
Department of Thoracic Surgery
Klinikum St Georg
Ostercappeln, Germanyb
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